SG10201900933YA - Koc1-derived peptide and vaccine including same - Google Patents
Koc1-derived peptide and vaccine including sameInfo
- Publication number
- SG10201900933YA SG10201900933YA SG10201900933YA SG10201900933YA SG10201900933YA SG 10201900933Y A SG10201900933Y A SG 10201900933YA SG 10201900933Y A SG10201900933Y A SG 10201900933YA SG 10201900933Y A SG10201900933Y A SG 10201900933YA SG 10201900933Y A SG10201900933Y A SG 10201900933YA
- Authority
- SG
- Singapore
- Prior art keywords
- peptides
- present
- cells
- koc1
- provides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 101100452137 Homo sapiens IGF2BP3 gene Proteins 0.000 abstract 1
- 102100037920 Insulin-like growth factor 2 mRNA-binding protein 3 Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014158919 | 2014-08-04 | ||
| JP2014158920 | 2014-08-04 | ||
| JP2014158921 | 2014-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201900933YA true SG10201900933YA (en) | 2019-02-27 |
Family
ID=55263772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700836TA SG11201700836TA (en) | 2014-08-04 | 2015-07-31 | Koc1-derived peptide and vaccine including same |
| SG10201900933YA SG10201900933YA (en) | 2014-08-04 | 2015-07-31 | Koc1-derived peptide and vaccine including same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700836TA SG11201700836TA (en) | 2014-08-04 | 2015-07-31 | Koc1-derived peptide and vaccine including same |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10576102B2 (ru) |
| EP (4) | EP3981416B1 (ru) |
| JP (2) | JP6754958B2 (ru) |
| KR (2) | KR20220155610A (ru) |
| CN (4) | CN106715461B (ru) |
| AU (2) | AU2015300256B2 (ru) |
| BR (1) | BR112017002206A2 (ru) |
| CA (1) | CA2956127A1 (ru) |
| DK (1) | DK3178838T3 (ru) |
| ES (1) | ES2753652T3 (ru) |
| IL (3) | IL250175B (ru) |
| MX (3) | MX2017001649A (ru) |
| RU (2) | RU2699542C2 (ru) |
| SG (2) | SG11201700836TA (ru) |
| TW (3) | TWI723958B (ru) |
| WO (1) | WO2016021506A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101943978B1 (ko) * | 2017-12-28 | 2019-01-30 | 주식회사 하이센스바이오 | 신규한 펩타이드 |
| TW202023581A (zh) * | 2018-08-02 | 2020-07-01 | 日商腫瘤療法 科學股份有限公司 | 來自cdca1的胜肽及含有此的疫苗 |
| CN112105724A (zh) * | 2018-08-09 | 2020-12-18 | 深圳华大生命科学研究院 | 无内源hla基因背景的抗原递呈细胞系的构建方法、抗原递呈细胞系及其用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| ATE319477T1 (de) | 1995-08-03 | 2006-03-15 | Univ Leiden | Antigen presentierende bläschen, die von zellen ableiten |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6294378B1 (en) | 1996-07-26 | 2001-09-25 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| US6255055B1 (en) * | 1998-03-09 | 2001-07-03 | Wisconsin Alumni Research Foundation | c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence |
| US20030236209A1 (en) | 1998-03-18 | 2003-12-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| ATE375362T1 (de) | 1998-06-25 | 2007-10-15 | Kyogo Itoh | Von cyclophilin b abstammende tumorantigen- peptide |
| EP1317275A1 (de) * | 2000-09-06 | 2003-06-11 | Müller, Friederike | Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors |
| WO2002072631A2 (en) | 2001-03-14 | 2002-09-19 | Dakocytomation Denmark A/S | Mhc molecule constructs and their usesfor diagnosis and therapy |
| JP2004000216A (ja) * | 2002-04-26 | 2004-01-08 | Kyogo Ito | 腫瘍抗原 |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| EP2343384A3 (en) | 2004-03-23 | 2012-01-04 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancer |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| EP1853703B1 (en) | 2005-02-25 | 2011-04-13 | Oncotherapy Science, Inc. | Peptide vaccines for lung cancers expressing ttk polypeptides |
| EP2298895A1 (en) | 2005-07-27 | 2011-03-23 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| CN101273144B (zh) | 2005-07-27 | 2011-12-28 | 肿瘤疗法科学股份有限公司 | 诊断食道癌的方法 |
| EP1930433B1 (en) | 2005-09-13 | 2016-03-16 | Mie University | T-cell receptor and nucleic acid encoding the receptor |
| WO2007097469A1 (en) | 2006-02-24 | 2007-08-30 | Oncotherapy Science, Inc. | A dominant negative peptide of imp-3, polynucleotide encoding the same, pharmaceutical composition containing the same, and methods for treating or preventing cancer |
| WO2008007711A1 (fr) * | 2006-07-11 | 2008-01-17 | Kurume University | Peptide dérivé de sart3, utile dans une thérapie du cancer par vaccin pour patient présentant un cancer de la prostate, positif á l'allèle hla-supertype a3 |
| EP2167536A1 (en) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
| TW201124530A (en) | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| JP5505943B2 (ja) | 2011-12-27 | 2014-05-28 | サミー株式会社 | スロットマシン |
| JP5505945B2 (ja) | 2011-12-27 | 2014-05-28 | サミー株式会社 | スロットマシン |
| JP5505944B2 (ja) | 2011-12-27 | 2014-05-28 | サミー株式会社 | スロットマシン |
| TWI627182B (zh) | 2013-05-24 | 2018-06-21 | 腫瘤療法 科學股份有限公司 | 對於ｔｈ１細胞之ｉｍｐ－３抗原決定位胜肽及含此之疫苗 |
-
2015
- 2015-07-31 CN CN201580052377.4A patent/CN106715461B/zh active Active
- 2015-07-31 RU RU2017106887A patent/RU2699542C2/ru active
- 2015-07-31 MX MX2017001649A patent/MX2017001649A/es active IP Right Grant
- 2015-07-31 SG SG11201700836TA patent/SG11201700836TA/en unknown
- 2015-07-31 DK DK15830118T patent/DK3178838T3/da active
- 2015-07-31 EP EP21202045.7A patent/EP3981416B1/en active Active
- 2015-07-31 US US15/501,125 patent/US10576102B2/en active Active
- 2015-07-31 JP JP2016540193A patent/JP6754958B2/ja active Active
- 2015-07-31 CN CN202010639945.3A patent/CN111925413A/zh active Pending
- 2015-07-31 CN CN202010639953.8A patent/CN111925414A/zh active Pending
- 2015-07-31 KR KR1020227039071A patent/KR20220155610A/ko not_active Application Discontinuation
- 2015-07-31 BR BR112017002206A patent/BR112017002206A2/pt not_active Application Discontinuation
- 2015-07-31 EP EP19186884.3A patent/EP3590954A3/en not_active Withdrawn
- 2015-07-31 AU AU2015300256A patent/AU2015300256B2/en not_active Ceased
- 2015-07-31 RU RU2019126629A patent/RU2019126629A/ru unknown
- 2015-07-31 CA CA2956127A patent/CA2956127A1/en not_active Abandoned
- 2015-07-31 SG SG10201900933YA patent/SG10201900933YA/en unknown
- 2015-07-31 WO PCT/JP2015/071829 patent/WO2016021506A1/ja active Application Filing
- 2015-07-31 EP EP15830118.4A patent/EP3178838B1/en active Active
- 2015-07-31 ES ES15830118T patent/ES2753652T3/es active Active
- 2015-07-31 EP EP24159394.6A patent/EP4353321A3/en active Pending
- 2015-07-31 CN CN202010640146.8A patent/CN111925431A/zh active Pending
- 2015-07-31 KR KR1020177006042A patent/KR102489834B1/ko active IP Right Grant
- 2015-08-04 TW TW104125176A patent/TWI723958B/zh active
- 2015-08-04 TW TW109106601A patent/TWI754234B/zh active
- 2015-08-04 TW TW110149598A patent/TW202219059A/zh unknown
-
2017
- 2017-01-18 IL IL250175A patent/IL250175B/en active IP Right Grant
- 2017-02-03 MX MX2020011561A patent/MX2020011561A/es unknown
- 2017-02-03 MX MX2020004418A patent/MX2020004418A/es unknown
-
2020
- 2020-01-27 US US16/773,487 patent/US11547723B2/en active Active
- 2020-04-08 AU AU2020202435A patent/AU2020202435B2/en not_active Expired - Fee Related
- 2020-07-20 JP JP2020123523A patent/JP7070945B2/ja active Active
-
2021
- 2021-01-26 IL IL280417A patent/IL280417B/en unknown
- 2021-11-10 IL IL287985A patent/IL287985A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| MX2022003698A (es) | Composiciones de nanoparticulas y metodos para inmunoterapia. | |
| ZA201900367B (en) | Formulation of a peptide vaccine | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
| MX366365B (es) | Peptidos de kntc2 y vacunas que los contienen. | |
| MX2017009289A (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
| EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
| UA114298C2 (uk) | Пептид торк та вакцина, що його містить | |
| SG10201900933YA (en) | Koc1-derived peptide and vaccine including same | |
| MX2022006022A (es) | Peptido derivado de depdc1 y vacuna que lo contiene. | |
| MX362912B (es) | Péptidos ube2t y vacunas que incluyen los mismos. | |
| SG10201900879PA (en) | Cdca1-derived peptide and vaccine containing same | |
| WO2016011432A3 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy | |
| SG10201900835XA (en) | Urlc10-derived peptide and vaccine containing same | |
| MX2021001357A (es) | Peptido derivado de cdca1 y vacuna que lo contiene. | |
| WO2015149016A3 (en) | Breast and ovarian cancer vaccines | |
| MX2017003949A (es) | Derivados peptidicos novedosos y sus usos. | |
| TW201613563A (en) | Bi-layer tablet formulations of cyclophosphamide and CAPECITABINE and highly fractionated METRONOMIC administration thereof | |
| BR112018006894A2 (pt) | peptídeo derivado de mphosph1 e vacina que inclui o mesmo | |
| MX2012011666A (es) | Peptidos cluap1 y vacunas que incluyen los mismos. |